21:52 , Oct 5, 2018 |  BC Extra  |  Preclinical News

Selecta's rapamycin nanoparticles could enable re-dosing of gene therapies

Selecta Biosciences Inc. (NASDAQ:SELB) showed its SVP-Rapamycin nanoparticles co-administered with an adeno-associated viral (AAV) vector-mediated transgene could enable repeat dosing of a gene therapy by suppressing the host’s immune response against the viral vector in...
22:27 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

RNA replaces enzymes

Moderna Therapeutics Inc. is continuing to build its pipeline of RNA alternatives to enzyme replacement therapies with a compound to treat the rare metabolic disease MMA. The goal is to provide more predictable kinetics and...
19:11 , May 19, 2017 |  BC Week In Review  |  Clinical News

Selecta's gene therapy improves survival in MMA mice

Selecta Biosciences Inc. (NASDAQ:SELB) said its Anc80-synMUT gene therapy corrected methylmalonyl CoA mutase (MUT) mutations and led to survival benefits in mouse models of methylmalonic acidemia (MMA). Selecta licensed the Anc80 vector on which the...